Inventiva

IVA

FR0013233012

Biotechnology & Medical Research

Real-time Euronext Paris Other stock markets 04:14:28 2025-12-17 EST			5-day change	1st Jan Change
3.755 ^EUR	-0.13%		-1.44%	+72.25%

11-28	JP Morgan Chase Surpasses 5% Stake in Inventiva
11-24	Inventiva Well-Positioned Following Treasury Update

Inventiva announces trading resumption on Euronext Paris

Published on 11/13/2025 at 10:31 am EST

Reuters

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Inventiva

11-28	JP Morgan Chase Surpasses 5% Stake in Inventiva
11-24	Inventiva Well-Positioned Following Treasury Update
11-24	KBC Maintains "Buy" Rating on Inventiva, Lowers Target Price
11-20	European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading	MT
11-17	Inventiva Boosts ADS Offering to $172 Million	MT
11-17	Full Exercise of Option for Inventiva's ADS Offering
11-14	French and Benelux stocks-Factors to watch	RE
11-13	Inventiva announces trading resumption of its ordinary shares on Euronext Paris	RE
11-13	Inventiva Resumes Trading on Euronext Paris	MT
11-13	France's Inventiva Prices, Upsizes $150 Million American Depositary Shares Offering	MT
11-13	Inventiva announces trading resumption on Euronext Paris	RE
11-13	Inventiva Sets Terms for U.S. ADS Offering
11-13	KBC Welcomes Inventiva's Fundraising Initiative
11-13	Inventiva Shares Pause Trading on Euronext Paris	MT
11-13	Inventiva Temporarily Suspends Trading on Euronext Paris
11-13	Inventiva Seeks $125 Million from US Public Offering of American Depositary Shares	MT
11-06	Wolfe Research Initiates Coverage on Inventiva SA ADR With Outperform Rating	MT
10-15	Inventiva Plans Up to $100 Million At-the-market Share Issuance Program	MT
10-14	Inventiva Files $300 Million Mixed Shelf	MT
10-14	Inventiva SA files for stock shelf of up to $300 million	RE
10-14	Inventiva announces the implementation of a new ATM program	RE
10-14	European Equities Traded in the US as American Depositary Receipts Edge Lower Tuesday	MT
10-09	Inventiva S.A. - Analyst/Investor Day
10-01	France's Inventiva Names New CEO	MT
10-01	Inventiva appoints Andrew Obenshain as chief executive officer	RE

Inventiva is a clinical-stage biopharmaceutical company focused on the research and development of oral small molecule therapies for the treatment of patients with MASH and other diseases with significant unmet medical need. The Company is currently evaluating lanifibranor, a novel pan-PPAR agonist, in the NATiV3 pivotal Phase 3 clinical trial for the treatment of adult patients with MASH, a common and progressive chronic liver disease. Inventiva owns an extensive library of approximately 240,000 pharmacologically relevant molecules, approximately 60% of which are proprietary, as well as a wholly owned research and development facility.

Employees

Sector

Biotechnology & Medical Research

Calendar

01-06 - MASH TAG Scientific Conference

More about the company